Please wait while we load the requested 10-K report or click the link below:
Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track
Conference Call and Webcast Today, March 13th at 8:30 a.m. ET
CINCINNATI Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017.
Over the past year, Aerpio has made tremendous progress in the development of AKB-9778, our first-in- class Tie2-activator, said Stephen Hoffman, MD, PhD, Chief Executive Officer of Aerpio. In June 2017, we initiated our TIME-2b Phase 2b study in patients with non-proliferative diabetic retinopathy (NPDR). The ability to delay or reverse the progression of NPDR to sight-threatening conditions, such as proliferative diabetic retinopathy and diabetic macular edema, is a significant unmet medical need. We have been very encouraged by the clinical communitys interest in AKB-9778s differentiated mechanism of action, its subcutaneous route of administration, and potential to treat multiple diabetic vascular comorbidities. In fact, we announced last month that we had completed enrollment in TIME-2b three months earlier than originally projected. We also recently reported preliminary data supporting the potential of AKB-9778 to protect the kidney vasculature in patients with diabetes. Additionally, based on findings from our previous Phase 2 trial with AKB-9778, we plan to begin clinical development for an eye drop formulation of AKB-9778 to treat primary open angle glaucoma within the next year.
Recent Company Highlights
|||Completed enrollment in the TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of the Companys lead candidate, AKB-9778, for patients with moderate-to- severe NPDR.|
|||Presented promising preliminary renal function data from the Companys Phase 2a TIME-2 clinical trial at the Keystone Symposium on Reducing the Burden of Diabetes Related End-Organ Injury.|
|||Successfully completed pre-IND meeting with the FDA for AKB-4924, a once-daily, oral HIF-1α stabilizer for treatment of ulcerative colitis, a form of inflammatory bowel disease.|
The following information was filed by Aerpio Pharmaceuticals, Inc. (ARPO) on Tuesday, March 13, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Aerpio Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Aerpio Pharmaceuticals, Inc..